Truist analyst Terry Tillman raised the firm’s price target on UiPath to $28 from $20 and keeps a Buy rating on the shares. The company’s Q3 results were “very strong” with upside in revenue, ARR and profitability, the analyst tells investors in a research note. UiPath is an automation leader and should benefit from notable GenAI interest owing to its differentiated approach of combining GenAI with Specialized AI, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PATH: